Study to Evaluate Efficacy and Safety of PENNEL Capsule in the Patients With Chronic Liver Disease
NCT ID: NCT01393678
Last Updated: 2011-07-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
220 participants
INTERVENTIONAL
1997-11-30
1998-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate Efficacy, Safety and Tolerability of PENNEL Capsule in the Patients With Chronic Liver Disease
NCT01393665
To Evaluate the Efficacy of DDB/Garlic Oil in Patients With Elevated Transaminase Chronic Liver Disease
NCT02347319
A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones).
NCT07005752
Clinical Trial to Evaluate the Efficacy and Safety of 'URSA SOFT CAP. (UDCA-003)' in Fatigue Patients With Liver Dysfunction
NCT02415777
The Effect of an RBAC Supplement (BRM4) on NAFLD
NCT02568787
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PENNEL
2cap T.I.D
PENNEL
Biphenyl Dimethyl Dicarboxylate 25mg \& garlic oil 50mg ............. 1cap
NISSEL
NISSEL
BDD (biphenylmethyl dicarboxylate) ................25mg
2cap T.I.D
NISSEL
Biphenyl Dimethyl Dicarboxylate 25mg ............. 1 cap
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NISSEL
Biphenyl Dimethyl Dicarboxylate 25mg ............. 1 cap
PENNEL
Biphenyl Dimethyl Dicarboxylate 25mg \& garlic oil 50mg ............. 1cap
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients over 20, under 65 years of age.
* Patients with abnormal transaminase value.
Exclusion Criteria
* Patients who have any history of esophageal bleeding, hepatic encephalopathy, ascites.
* Diabetes, thyroid dysfunction, fatty liver, liver cancer patients.
* Toxic hepatitis, alcoholic hepatitis.
* Total bilirubin value more than 3.0 mg/dl.
* Albumin value less than 3.0 g/dl.
* Patients who participating in other study about drug.
20 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PharmaKing
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
CR team
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Minho Lee, MD.PhD
Role: PRINCIPAL_INVESTIGATOR
Hanyang University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hanyang University Hospital
Seoul, Seongdong-gu,, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PMK-PENNEL 3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.